文献速递肾移植

法国SOT COVID登记处初步报告:肾移植受者感染COVID-19死亡率高

An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants.
PubMed 文献 · Kidney Int · 2020-08-24

该登记研究纳入279例肾移植受者,其中243例住院,住院患者中位年龄61.6岁,多合并高血压、超重、糖尿病。46%发生重症COVID-19,住院患者30天死亡率为22.8%。超重、发热、呼吸困难是重症独立危险因素,年龄>60岁、心血管疾病、呼吸困难与死亡独立相关。

要点

  • 肾移植受者感染COVID-19重症率和死亡率高。
  • 超重、发热、呼吸困难提示重症风险。
  • 年龄>60岁、心血管疾病、呼吸困难与死亡相关。

核心结论

  • 肾移植受者感染COVID-19预后差,死亡率高,免疫抑制管理及个体化治疗仍具挑战。

研究设计与样本

  • 基于法国全国实体器官移植受者COVID-19登记处的观察性研究,纳入279例肾移植受者。

主要发现

  • 279例中243例住院,36例居家管理;住院患者中位年龄61.6岁。
  • 住院患者合并症常见:高血压90.1%、超重63.8%、糖尿病41.3%、心血管疾病36.2%。
  • 106例(46%)发生重症COVID-19,43例住院患者死亡,30天死亡率22.8%。
  • 多变量分析显示超重、发热、呼吸困难是重症独立危险因素;年龄>60岁、心血管疾病、呼吸困难与死亡独立相关。

关键数值与推荐

  • 免疫抑制剂普遍调整:钙调神经磷酸酶抑制剂停用28.7%,抗代谢药停用70.8%。
  • 治疗以羟氯喹(24.7%)、抗病毒药物(7.8%)、托珠单抗(5.3%)为主。

临床怎么用

  • 对肾移植受者应警惕COVID-19重症风险,尤其超重、发热、呼吸困难者。
  • 年龄>60岁或合并心血管疾病的肾移植受者感染后死亡风险更高,需密切监测。
  • 免疫抑制剂的调整需权衡风险,目前管理仍具挑战性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information on its clinical presentation and prognosis in recipients of a kidney transplant remain scanty. The aim of this registry-based observational study was to explore characteristics and clinical outcomes of recipients of kidney transplants included in the French nationwide Registry of Solid Organ Transplant Recipients with Covid-19. Covid-19 was diagnosed in symptomatic patients who had a positive PCR assay for SARS-CoV-2 or having typical lung lesions on imaging. Clinical and laboratory characteristics, management of immunosuppression, treatment for Covid-19, and clinical outcomes (hospitalization, admission to intensive care unit, mechanical ventilation, or death) were recorded. Risk factors for severe disease or death were determined. Of the 279 patients, 243 were admitted to hospital and 36 were managed at home. The median age of hospitalized patients was 61.6 years; most had comorbidities (hypertension, 90.1%; overweight, 63.8%; diabetes, 41.3%; cardiovascular disease, 36.2%). Fever, cough, dyspnea, and diarrhea were the most common symptoms on admission. Laboratory findings revealed mild inflammation frequently accompanied by lymphopenia. Immunosuppressive drugs were generally withdrawn (calcineurin inhibitors: 28.7%; antimetabolites: 70.8%). Treatment was mainly based on hydroxychloroquine (24.7%), antiviral drugs (7.8%), and tocilizumab (5.3%). Severe Covid-19 occurred in 106 patients (46%). Forty-three hospitalized patients died (30-day mortality 22.8%). Multivariable analysis identified overweight, fever, and dyspnea as independent risk factors for severe disease, whereas age over 60 years, cardiovascular disease, and dyspnea were independently associated with mortality. Thus, Covid-19 in recipients of kidney transplants portends a high mortality rate. Proper management of immunosuppression and tailored treatment of this population remain challenging.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Caillard S, Anglicheau D, Matignon M, et al. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int. 2020. PMID: 32853631. doi:10.1016/j.kint.2020.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。